Associated tags: Patient, Pharmaceutical industry, Zenith, Carcinoma, BET, Diagnosis, Head, Survival, Disease, NUT carcinoma, Cancer, Quality of life, Prognosis, Neck, National Cancer Institute, NUT
Retrieved on:
Thursday, February 29, 2024
Rare disease,
Head,
NUT,
Aggression,
Neck,
Quality of life,
Health,
Zenith,
Cell,
Prevalence,
Prognosis,
Patient,
Nervous tissue,
Clinical trial,
NUT carcinoma,
Disease,
Survival,
Sympathetic nervous system,
Diagnosis,
Metastasis,
BET,
Carcinoma,
Cancer,
Pharmaceutical industry ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications
Key Points:
- Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
- Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
- This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
- We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
Retrieved on:
Thursday, October 26, 2023
UCSF,
Eli Lilly,
Zenith,
National Institutes of Health,
Monroe Dunaway Anderson,
Merck,
International commercial law,
BMS,
Pfizer,
National Cancer Institute,
GSK,
Eye,
AmerisourceBergen,
Patient,
Pharmaceutical industry,
Nursing,
Astellas Pharma,
Yale University Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program.
Key Points:
- Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program.
- The ZEN-3694 program is an advanced epigenetic approach to synergistically advancing the efficacy of cancer treatment of currently marketed drugs.
- As part of the agreement, Cencora will provide a variety of services to strategize ZEN-3694's market introduction.
- While Zenith continues its work on ZEN-3694's technology platform, Cencora's teams will identify key avenues and opportunities for ZEN-3694's commercialization and market entry.
CRPC,
Neoplasm,
Survival,
NUT,
CRADA,
Quality of life,
Lung cancer,
Head,
Prognosis,
Carcinoma,
NUT carcinoma,
Neck,
Bangladesh Technical Education Board,
BET,
Development,
National Cancer Institute,
Cancer,
Cooperative research and development agreement,
Patient,
Colorectal cancer,
Drug combination,
Zenith,
Diagnosis,
CTEP,
Ovarian cancer,
Breast cancer,
NCI,
NIH,
Disease,
Pharmaceutical industry Zenith's BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type
Key Points:
- Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC).
- Zenith Epigenetics has provided ZEN-3694 to two NC patients for compassionate use and both experienced significant clinical benefit and durable reduction of their tumors.
- "We are very pleased that NUT carcinoma patients receiving ZEN-3694 for compassionate use have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
- We continue to advance these programs with our partners and are committed to bring this important therapy to these patients."
